A BST RACT : Background: Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent. Method: We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale. Results: Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile 5 0.70; 95% confidence interval, 0.57-0.86; p < .001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p < .01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p 5 .47; p RERI 5 .43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk. Conclusion: Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk. 
A BST RACT : Background: Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent. Method: We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale. Results: Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile 5 0.70; 95% confidence interval, 0.57-0.86; p < .001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p < .01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p 5 .47; p RERI 5 .43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk. Conclusion: Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk. Numerous cohort and case-control studies have suggested a large environmental component in predicting Parkinson's disease (PD) risk. 1, 2 Among these determinants, caffeine intake is one of the most well-established protective factors of PD. [3] [4] [5] [6] [7] [8] In 2011, Hamza and colleagues 9 conducted a genome-wide association and interaction study in PD with the joint test for each single nucleotide polymorphisms (SNP's) main effect and its interaction with coffee. The investigators identified rs4998386 (C->T) and 11 neighboring SNPs in the glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) gene to have significant interactions with caffeine on PD risk. This interaction is intriguing because GRIN2A encodes a subunit of the N-methyl-D-aspartate glutamate receptor that regulates excitatory neurotransmissions in the brain and could thus plausibly influence the course of neurodegeneration leading to PD. [10] [11] [12] The results of subsequent studies, however, have failed to confirm this interaction; in an investigation in Sweden, a significant interaction was observed in the opposite direction, 13 whereas in a third investigation in a pooled, diverse population from Rochester, Seattle, France, and Denmark, no interactions were found. 14 Similarly conflicting results were reported on the caffeine-gene interaction with cytochrome P450 1A2 (CYP1A2), [15] [16] [17] [18] which encodes the cytochrome P450 CYP1A2 enzyme that is responsible for metabolizing more than 90% of caffeine into paraxanthine. 19, 20 Individuals with the rs762551 A->C SNP have lower CYP1A2 inducibility, rendering slower caffeine metabolism.
Important limitations of the previous studies include the uncertain representativeness of the control groups, the inclusion of prevalent cases of PD, and insufficient matching and adjustment of confounders and that caffeine consumption was largely assessed retrospectively.
Therefore, we evaluated the presence of additive and multiplicative interaction between caffeine intake and GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms on PD risk in a case-control study nested within 3 longitudinal cohorts.
Methods

Study Population
The current study was composed of participants who provided blood or buccal cell samples from the following 3 longitudinal cohorts: the Nurses' Health Study (NHS), the Health Professionals Follow-up Study (HPFS), and the Cancer Prevention Study II Nutrition Survey cohort (CPS-IIN).
In 1976, the NHS enrolled 121,700 female registered nurses aged 30 to 55 years who returned mailed, selfadministered questionnaires regarding lifestyle factors and disease occurrence. In 1986, the HPFS enrolled 51,529 male health professionals aged 40 to 75 years who returned similar questionnaires as in the NHS; these questionnaires were collected every 2 years for both cohorts. Nutritional information, including coffee consumption and other caffeinated beverages, was ascertained via validated semiquantitative food frequency questionnaires generally every 4 years for the NHS and HPFS, with an approximately 94% overall response rate. 21 
PD Case Ascertainment and Control Selection
Individuals who reported PD via biennial self-report questionnaires were asked for permission to contact their neurologist to confirm their diagnoses. We then contacted patients' neurologists and requested for them to either return a self-administered diagnostic questionnaire that asked to confirm the case or to send a copy of the patient's medical records. In the years prior to 2003, PD cases were considered confirmed if the treating neurologist considered the diagnosis as definite or probable, the final diagnosis of PD by a neurologist was included in the medical record, or the medical record indicated the presence of at least
2 out of 4 cardinal signs of PD (among which, 1 being resting tremor or bradykinesia) in the absence of features indicating other diagnoses. After 2003, a similar procedure was used to identify confirmed PD case with the exception that the medical records were requested from all PD cases and reviewed by a neurologist specializing in movement disorders. We used the diagnosis of the neurologist specializing in movement disorders to determine cases if it differed from that of the original neurologist. Only confirmed cases were included in the analyses. In NHS and HPFS, between 2 and 6 controls who were alive on the date of case diagnosis and had never reported a diagnosis of PD were randomly selected and matched to the case; for the CPS-IIN cohort, 1 control was selected per case. Within each cohort, we matched the controls to cases based on sex, birth year (61 year), race (white vs other), source of DNA (blood or buccal smear), and, for participants with blood samples, fasting status (>8 hours vs less or unknown) and time of blood draw (in 2-hour intervals).
Caffeine and Other Covariate Assessment
Information on lifestyle practices, such as smoking status and physical activity, was collected biennially by self-report questionnaires for all cohorts. Dietary data, including coffee and caffeine intake, was collected via self-administered semiquantitative food frequency questionnaires (FFQ) every 4 years for the NHS and HPFS. The semiquantitative FFQ captured average intake pattern of food and beverages during the past 12 months using 9 possible multiple-choice responses for each item's intake frequency, ranging from "never or less than once per month" to "6 or more times per day." Information on coffee and caffeine was comprehensively assessed on the 1999 FFQ for the CPS-IIN; therefore, we considered 1999 as the study baseline for the CPS-IIN.
We used the U.S. Department of Agriculture food composition sources to estimate participants' reported average intake of one serving of a caffeinated beverage or food into total daily average intake of caffeine using the following caffeine content values: 137 mg caffeine per cup of coffee, 47 mg of caffeine per cup of 
Laboratory Analyses
Genomic DNA was extracted from buffy coat with QIAamp (Qiagen Inc, Chatsworth, California), which was then genotyped using the TaqMan assay on the ABI PRISM 7900HT Sequence Detection System, a high-throughput real-time polymerase chase reaction (PCR) system (Applied Biosystems, Foster City, California).
Statistical Analysis
We tested the Hardy-Weinberg equilibrium assumption for both the rs4998386 and rs762551 SNP using a v 2 test comparing the observed to expected genotype frequencies in all of the cohorts. Conditional logistic regression models, which adjust for matching factors, were used to estimate relative risks (RRs) and corresponding 95% confidence intervals (CIs) to assess the association between each of the exposure categories and PD risk.
Using cohort-specific distributions of covariates, we dichotomized total caffeine intake (most recent intake relative to the date of diagnosis for the NHS and HPFS; at baseline for the CPS-IIN) as high caffeine intake compared to low caffeine intake at the median intake level among controls (366.0 mg/day for NHS; 156.5 mg/day for HPFS, 80.8 mg/day for CPS II-N). In addition, we used cohort-specific tertiles of caffeine intake and, in selected analyses, caffeine as a continuous variable. Physical activity was dichotomized at each cohort's respective median levels and smoking status was categorized as never/ever. Because the homozygous TT genotype of the rs4998396 SNP was very rare in all of our cohorts (<1%), the CT and TT genotypes were combined for the dominant model of inheritance (ie, CC vs CT/TT). The exposure categories were composed of the 4 possible combinations of the GRIN2A SNP genotypes and dichotomized caffeine levels, among which the reference was the category with low caffeine intake and having a TT or CT genotype (the category with lowest PD risk). This design allowed us to calculate the following 2 indices of additive interaction: relative excess risk due to interaction (RERI) and the attributable proportion due to interaction (AP). RERI measures whether the joint effect of both exposures is greater than the combined effects of individual exposures, whereas AP measures the proportion of the combined effect as a result of the interaction. An RERI and AP of 0 suggests exact additivity (ie, no additive interaction), an RERI or AP >0 indicates the presence of super-additive interaction, and an RERI or AP <0 of subadditive interaction. We calculated the RERI and AP and their 95% CIs by inserting the regression coefficients and covariance matrix from the conditional logistic regression models using SAS (SAS Institute, Cary, North Carolina) into an Excel (Microsoft, Redmond, Washington) spreadsheet proposed by Andersson and colleagues. 26 To conduct tests of additive interactions, we reversed the 27 In addition, we performed tests of multiplicative interaction between dichotomized caffeine intake and the GRIN2A SNP genotype on the risk of PD by testing the significance of the product term between the SNP and caffeine intake. Multiplicative interaction was also assessed using continuous caffeine intake (per additional 100 mg/day) because of the large variation in caffeine intake across cohorts.
We conducted analyses separately for the NHS and HPFS in addition to combining them to increase power. Because the CPS-IIN lacked sufficient genotyped data, we could not perform cohort-specific analyses for the GRIN2A SNP. Rather, we performed analyses including the CPS-IIN cohort with the health professional cohorts. Because genotyping information for the rs762551 SNP was not available in the CPS-IIN, we performed similar interaction analyses only in the NHS and HPFS using an additive model of inheritance (ie, per increasing minor allele). We conducted similar analyses with coffee because it is the main source of caffeine in the cohorts. All statistical analyses were conducted using SAS version 9.4 (SAS Institute).
Results
A total of 829 incident PD cases (286 from HPFS, 393 from NHS, 150 from CPS-IIN) were documented and matched with 2,754 controls. The genotype and allele frequencies of the GRIN2A SNP rs4998386 were comparable between cases and controls, and the Hardy-Weinberg equilibrium assumption was confirmed in all cohorts (P > .05; Table 1 ). Although there was a trend toward a protective effect among homozygous CC carriers, there was no significant association between the genotype frequencies and PD risk under the dominant model in any of the cohorts. In the combined cohorts (NHS, HPFS, and CPS-IIN), participants had a 7% reduced risk of PD per increasing 100 mg/ day of caffeine intake, adjusting for the matching factors (RR 5 0.93; 95% CI; 0.89-0.98; P < .01; Fig. 1) .
The results of the joint effects of GRIN2A SNP genotype and total caffeine intake in the combined cohorts are presented in Supplementary Table 1 . Participants with the GRIN2A-rs4998386_CC genotype and high caffeine intake had a 26% reduced risk when compared with a referent group with a CT/TT genotype and low caffeine intake (RR 5 0.74; 95% CI, 0.56-0.99; P 5 .04). In addition, participants with high caffeine intake had 19% reduced risk of PD when compared with those with low caffeine intake among CC carriers (RR 5 0.81; 95% CI, 0.67-0.97; When assessing caffeine intake in tertiles, we found that CC carriers with the highest tertile of caffeine intake had 0.60 times the PD risk when compared with CT/TT carriers with the lowest tertile of caffeine intake (95% CI, 0.42-0.86; P < .01; Supplementary Table 2) . Furthermore, among CC carriers, participants in higher tertiles of caffeine consumption had a significantly decreased risk of PD when compared with participants who had the lowest tertile of caffeine consumption (RR 2vs1 5 0.77; 95% CI, 0.62-0.96; P 5 .02; RR 3vs1 5 0.66; 95%CI, 0.52-0.83; P < .001). However, neither additive interaction nor multiplicative interaction was detected. Further adjustment for smoking status and physical activity did not change results ( Table 3) . The results of cohort-specific associations are presented in Supplementary Tables 3a-d .
In addition, we tested the caffeine interaction with the CYP1A2 rs762551 polymorphism on PD risk. In the NHS, each increasing minor allele of the CYP1A2 polymorphism was associated with a 42% increased PD risk (P 5 .02). However, no significant additive or multiplicative interactions were found between the CYP1A2 rs762551 polymorphism and caffeine on PD risk in any of the cohorts (Table 4 and Supplementary  Tables 4-6 ).
Discussion
In our present study of 3 large, prospective cohorts, we found no evidence of an interaction between caffeine intake and GRIN2A rs4998386 or CYP1A2 rs762551 polymorphisms in determining PD risk.
Consistent with the results of previous studies, PD risk decreased with increasing caffeine intake, but this inverse association was similar across genotypes of GRIN2A and CYP1A2, which did not significantly contribute to predict PD risk. In our cohorts, PD risk tended to be lower among carriers of the GRIN2A rs4998386_CC genotype, whereas a couple of previous studies reported a trend toward a protective effect of the T allele. 9, 13 Overall, these results are consistent with chance fluctuations and suggest that GRIN2A is not a determinant of PD risk and does not modify the effects of caffeine. Although the median caffeine intake among our 3 cohorts varied widely, the results were consistent across cohorts without significant heterogeneity in RR estimates.
A limitation of our study is that we may not have had enough power to detect a caffeine-GRIN2A SNP interaction on PD risk. Interaction studies generally require substantially larger sample sizes compared to those required to detect a main effect of the same magnitude; this may explain our lack of association in our cohorts, as Hamza and colleagues 9 performed pooled analyses among 2,474 cases and 2,848 controls. However, the fact that previous studies reached opposite conclusions with regard to the interaction between caffeine and GRIN2A (ie, inverse association between caffeine and PD was stronger among carrier of the T allele in 1 study, 9 but among homozygous for the C allele in the others, 13, 14 Supplementary Table 7 ) is consistent with the conclusion that the relation between caffeine and PD risk is unlikely to be substantially modified by GRIN2A.
Finally, we found that the CYP1A2 rs762551 SNP was associated with an increased risk in the NHS, but not in the HPFS. No interaction was detected between the SNP and caffeine intake on PD risk, which is consistent with studies across multiple cohorts. 15, 16, 18 The main strengths of our study include our nested case-control study design with prospectively collected data. Furthermore, we performed interaction analyses on the multiplicative and additive scales, which could provide more insight and lead to a better understanding of the biological mechanism through which multiple factors are involved in disease pathogenesis. A limitation of our study is the restricted generalizability of our results to other populations, as the participants in our cohorts are predominantly of European descent. However, our homogenous population is instrumental in reducing the risk of confounding by population stratification bias.
In conclusion, our results do not support the hypotheses that caffeine consumption interacts with GRIN2A-rs4998386 SNP or with CYP1A2-rs726551 polymorphisms to affect PD risk.
